RESUMO
This study aims to estimate the COVID-19 vaccine acceptance and hesitancy among people living with HIV (PLWHA). A search for observational studies was conducted in five databases and preprinted literature. Summary estimates were pooled using a random effects model and meta-regression. Of 150 identified studies, 31 were eligible (18,550 PLWHA). The weighted prevalence of COVID-19 vaccine hesitancy overall was 29.07% among PLWHA (95%CI = 24.33-34.32; I² = 98%,) and that of vaccine acceptance was 68.66% (95%CI = 62.25-74.43; I² = 98%). Higher hesitancy prevalence was identified in low/lower-middle income countries (35.05; 95% CI = 19.38-54.78). The heterogeneity was explained by the risk of bias, region, and year of data collection. The findings conclude that the COVID-19 vaccine hesitancy rate remains high, especially in low-income countries. Evidence-informed interventions aimed at increasing COVID-19 vaccine acceptance at the national and individual levels ought to be designed to increase COVID-19 vaccine acceptance among PLWHA.
Assuntos
Vacinas contra COVID-19 , COVID-19 , Infecções por HIV , SARS-CoV-2 , Hesitação Vacinal , Humanos , Vacinas contra COVID-19/administração & dosagem , Infecções por HIV/psicologia , Infecções por HIV/prevenção & controle , Infecções por HIV/epidemiologia , COVID-19/prevenção & controle , COVID-19/epidemiologia , COVID-19/psicologia , Hesitação Vacinal/psicologia , Hesitação Vacinal/estatística & dados numéricos , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Países em Desenvolvimento , Vacinação/psicologia , Vacinação/estatística & dados numéricosRESUMO
We discuss the quality of the article evidence on the association between vitamin D deficiency and COVID-19, as well as updating the statistics in response to the letter to the editor regarding the same paper. Our review included 22 studies with data available in 23 articles. Using crude OR data, we observed that the chance of hospitalization was 2.16 (CI 95% = 1.42 - 2.89;) for vitamin-deficient individuals compared to non-deficient ones. However, when using the adjusted OR, it was possible to obtain a chance of 1.78 (CI 95% = 1.36-2.20). For the outcome vitamin D deficiency and death in patients with COVID-19 infection the crude association value was 1.38 (OR =1.38; CI 95% = 1.08 - 1.68) and the adjusted OR with the two studies was 1.08 (CI 95% = 0.82- 1.34). This new analyzes don't substantially alter our results. Vitamin D remains associated with severity COVID-19.
Assuntos
COVID-19 , Deficiência de Vitamina D , Humanos , COVID-19/complicações , Deficiência de Vitamina D/complicações , Vitamina D , VitaminasRESUMO
There is still limited evidence regarding the influence of vitamin D in people with COVID-19. In this systematic review and meta-analysis, we analyze the association between vitamin D deficiency and COVID-19 severity, via an analysis of the prevalence of vitamin D deficiency and insufficiency in people with the disease. Five online databases-Embase, PubMed, Scopus, Web of Science, ScienceDirect and pre-print Medrevix were searched. The inclusion criteria were observational studies measuring serum vitamin D in adult and elderly subjects with COVID-19. The main outcome was the prevalence of vitamin D deficiency in severe cases of COVID-19. We carried out a meta-analysis with random effect measures. We identified 1542 articles and selected 27. Vitamin D deficiency was not associated with a higher chance of infection by COVID-19 (OR = 1.35; 95% CI = 0.80-1.88), but we identified that severe cases of COVID-19 present 64% (OR = 1.64; 95% CI = 1.30-2.09) more vitamin D deficiency compared with mild cases. A vitamin D concentration insufficiency increased hospitalization (OR = 1.81, 95% CI = 1.41-2.21) and mortality from COVID-19 (OR = 1.82, 95% CI = 1.06-2.58). We observed a positive association between vitamin D deficiency and the severity of the disease.